Infrastructure for the next generation cannabinoid-based therapies.
Heimat is developing the infrastructural conditions for the future development, manufacturing and supply of cannabinoid-based medicinal products.
Existing capabilities in manufacturing, cultivation, quality, documentation and market access are progressively combined into a pharma-oriented infrastructure.
The goal is a scalable platform for applications in the healthcare and pharmaceutical market.
Pharma begins with infrastructure.
Manufacturing
Standardised and documented manufacturing processes.
Quality
Defined quality, testing and documentation processes.
Regulatory affairs
Progressive build-up of the conditions for pharmaceutical quality requirements.
Traceability
Documentation of raw materials, processes and batches along the value chain.
Building pharma-oriented infrastructure.
Supply channel
Building and testing controlled supply structures via the pharmacy market.
Data and documentation
Systematic capture of operational data, quality parameters and supply experience.
Product and therapy development
Development of defined active ingredient profiles, standardised formulations and reproducible product quality.
Pharmaceutical scaling
Preparation of quality, manufacturing and documentation systems for future pharmaceutical applications.
Existing infrastructure for building the medical cannabis module.
Manufacturing infrastructure
Industrial manufacturing and processing capability at the Steinach site.
Own cultivation
Controlled indoor and outdoor cultivation as the basis for defined raw material qualities.
Pharmacy access
Existing structures for the development and market launch of pharmacy-suitable products.
Module development
Systematic connection of manufacturing, quality, documentation and healthcare market access.
Where Heimat stands today and how the infrastructure is being developed further.
Existing infrastructure
- Manufacturing infrastructure
- Cultivation
- Quality and batch documentation
- Pharmacy and healthcare market access
- Product development and white label
Ongoing development areas
- Medical cannabis module
- Pharma-oriented quality systems
- Standardised active ingredient and product profiles
- Medical and scientific partnerships
Strategic ambition, not a current status
- GMP-compliant manufacturing structures
- Cannabinoid-based medicinal products
- Scalable pharmaceutical supply
From healthcare market access to pharma-oriented infrastructure.
The pharmacy and healthcare channel forms the operational starting point. Building on this, Heimat is developing a medical cannabis module that connects cultivation, manufacturing, quality, documentation and market access.
The long-term goal is a scalable infrastructure for standardised cannabinoid-based products, medical applications and future pharmaceutical supply solutions.
Let's talk aboutCollaboration.
Whether market access, manufacturing, white label, technology or strategic partnership: speak with our team about joint projects in regulated markets.